Non-Covid drugs and vaccines likely to get fast-track approval too

A senior CDSCO official confirmed that there are plans to adopt the best practices used during the Covid-19 pandemic for non-Covid19 drugs too

The domestic pharma industry has urged the Central Drugs Standards Control Organisation (CDSCO) to consider extending the fast-track approval process adopted during Covid-19 for vaccines and even drugs that were re-purposed for treating Covid-19 patients, to non-Covid drugs as well.

Multiple industry sources confirmed the development. The head of a pharma lobby group told Business Standard, “During Covid19, the CDSCO had adopted a fast-track and rolling review system for approving essential drugs and vaccines that were needed urgently for treating patients. Drugs such as remdesivir or favipiravir, etc, are a case in point. The industry has requested that such best practices